From: Screening for an ivermectin slow-release formulation suitable for malaria vector control
Group | Mean daily dose | Tmax | Cmax | AUC 12 weeks | AUC 24 weeks | Time >7 ng/ml |
---|---|---|---|---|---|---|
1 F | 64 (60–77) | 2 (1–2) | 7 (7–10) | 66 (61–68) | - | 3 (1–3) |
2 F | 76 (75–105) | 1 (1–2) | 16 (12–16) | 120 (113–163) | - | 12 (11–12) |
3 F | 75 (70–85) | 1 (1–2) | 22 (19–36) | 155 (153–348) | 277 (266–615) | 24 (24) |
1 M | 34 (31–43) | 7 (7–11) | 13 (4–20) | 81 (38–126) | - | 3 (0–11) |
2 M | 83 (77–91) | 2 (1–3) | 16 (14–20) | 122 (106–164) | - | 12 (8–12) |
3 M | 69 (63–73) | 1 (1–2) | 22 (16–33) | 164 (160–224) | 300 (278–403) | 24 (24) |
1X | 30 (29–32) | 3 (2–8) | 12 (8–14) | 79 (63–85) | - | 2 (1–3) |
2X | 30 (27–34) | 4 (3–4) | 17 (17–35) | 170 (152–311) | 218 (207–404) | 12 (12–16) |
3X | 43 (41–49) | 3 (2–7) | 42 (35–85) | 307 (306–497) | 422 (393–620) | 16 (16) |